Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Wallen, Herschel ^a   Thompson, John A ^a   Reilly, J Zachary ^a   Rodmyre, Rebecca M ^a   Cao, Jianhong ^a   Yee, Cassian ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FLUDARABINE; INTERLEUKIN 15; INTERLEUKIN 7; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT; CYTOKINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DRUG DERIVATIVE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; VIDARABINE;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELL THERAPY; CELL TRANSFER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; GRAFT SURVIVAL; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; LYMPHOCYTOPENIA; MELANOMA; METASTASIS POTENTIAL; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TREATMENT DURATION; TREATMENT RESPONSE; ADOPTIVE IMMUNOTHERAPY; DRUG ANTAGONISM; DRUG RESISTANCE; IMMUNOLOGY; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; TRANSPLANTATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DRUG RESISTANCE, NEOPLASM; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS; TREATMENT OUTCOME; VIDARABINE;

EID: 62749185585     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004749     Document Type: Article

References (31)

1. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, et al. (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99: 16168-16173.
2. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, et al. (2006) Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24: 5060-5069.
3. Michalek J, Kocak I, Fait V, Zaloudik J, Hajek R (2007) Detection and long-term in vivo monitoring of individual tumor-specific T cell clones in patients with metastatic melanoma. J Immunol 178: 6789-6795.
4. Tan JT, Ernst B, Kieper WC, LeRoy E, Sprent J, et al. (2002) Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med 195: 1523-1532.
5. Prlic M, Lefrancois L, Jameson SC (2002) Multiple choices: regulation of memory CD8 T cell generation and homeostasis by interleukin (IL)-7 and IL-15. [letter; comment.]. Journal of Experimental Medicine 195: F49-52.
6. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, et al. (2002) Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. Journal of Immunology 168: 4272-4276.
7. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, et al. (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. Journal of Experimental Medicine 194: 823-832.
8. Greenberg PD (1986) Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia. Journal of Immunology 136: 1917-1922.
9. North RJ, Awwad M (1987) T cell suppression as an obstacle to immunologically-mediated tumor regression: elimination of suppression results in regression. Prog Clin Biol Res 244: 345-358.
10. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
11. Cheson BD (1995) Infectious and immunosuppressive complications of purine analog therapy. Journal of Clinical Oncology 13: 2431-2448.
12. Kish JA, Kopecky K, Samson MK, Von Hoff DD, Fletcher WS, et al. (1991) Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group study. Invest New Drugs 9: 105-108.
13. Vlasveld LT, Horenblas S, Hekman A, Hilton AM, Dubbelman AC, et al. (1994) Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. Annals of Oncology 5: 179-181.
14. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, et al. (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181.
15. Jaffe CC (2006) Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24: 3245-3251.
16. Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, et al. (1996) Phenotypic analysis of antigen-specific T lymphocytes [published erratum appears in Science 1998 Jun 19;280(5371):1821]. Science 274: 94-96.
17. Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, et al. (2000) Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods 244: 81-89.
18. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, et al. (2000) Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med 192: 1637-1644.
19. Weber J (2007) Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12: 864-872.
20. Liu W, Putnam AL, Zhou X, Szot GL, et al. (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203: 1701-1711.
21. Dubois S, Mariner J, Waldmann TA, Tagaya Y (2002) IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17: 537-547.
22. Liberman AC, Refojo D, Druker J, Toscano M, Rein T, et al. (2007) The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction. Faseb J 21: 1177-1188.
23. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM (2006) Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T-cells in B-cell non-Hodgkin lymphoma. Blood 107: 3639-3646.
24. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
25. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, et al. (2004) Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173: 1444-1453.
26. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, et al. (2005) Reduced frequencies and suppressive function of CD4+ CD25high regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106: 2018-2025.
27. Stanzer S, Dandachi N, Balic M, Resel M, Samonigg H, et al. (2007) Resistance to Apoptosis and Expansion of Regulatory T Cells in Relation to the Detection of Circulating Tumor Cells in Patients with Metastatic Epithelial Cancer. J Clin Immunol.
28. Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, et al. (2005) Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 11: 1238-1243.
29. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357.
30. Balch CM, A.N. H, Sober AJ, Soong S (1998) Cutaneous Melanoma. St. Louis MO: Quality Medical Publishing Corporation. 596 p.
31. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA (2005) Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28: 582-592.